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Oncolytic viruses (OVs) not only kill cancer cells by direct lysis but also generate a signif-
icant anti-tumor immune response that allows for prolonged cancer control and in some
cases cures. How to best stimulate this effect is a subject of intense investigation in the OV
field. While pharmacological manipulation of the cellular innate anti-viral immune response
has been shown by several groups to improve viral oncolysis and spread, it is increasingly
clear that pharmacological agents can also impact the anti-tumor immune response gener-
ated by OVs and related tumor vaccination strategies. This review covers recent progress
in using pharmacological agents to improve the activity of OVs and their ability to generate
robust anti-tumor immune responses.
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INTRODUCTION: ONCOLYTIC VIRUSES: MULTI-MECHANISTIC
BIOTHERAPEUTICS AGAINST CANCER
Oncolytic viruses (OVs) are self-amplifying biotherapeutics that
have been selected or engineered to preferentially infect and
kill cancer cells. Generated from a multitude of viral species,
OVs exploit cancer-associated cellular defects arising from genetic
perturbations including mutations and epigenetic reprograming
[reviewed in Ref. (1)]. Among others, these cellular defects lead to
dysfunctional anti-viral responses and immune evasion, increased
cell proliferation and metabolism, and leaky tumor vasculature
(2). These characteristics in turn provide a fertile ground for viral
replication and subsequent lysis of tumor cells and permit the
growth of genetically attenuated OVs that are otherwise harmless
to normal cells.
In addition to the direct killing of cancer cells, OVs can also
trigger a potent anti-tumor immune response. Infected tumor
cells induce the release of pro-inflammatory cytokines and expose
both viral and tumor-associated antigens to patrolling immune
cells, promoting the differentiation of antigen-presenting cells and
T-cell activation (3–5). How much tumor infection and lysis are
necessary to trigger these responses remains a topic of debate;
however, it is clear that the combination of direct oncolysis and
activation of anti-tumor immunity can lead to durable cures in
pre-clinical mouse models of cancer.
A number of OVs are currently being evaluated in clinical
trials to treat a range of cancer types. For a more compre-
hensive overview, the reader is invited to consult an excellent
review by Russell et al. (6). Of particular note, herpes simplex
virus-1 (HSV-1), vaccinia virus, reovirus, and adenovirus-based
OV strains have made the most progress toward approval (7–
10). Shanghai Sunway Biotech’s oncolytic adenovirus (H101),
deleted for the viral E1B gene and thought to target p53 defi-
cient cancer cells, was the first approved OV in China as early
as 2005, indicated for head and neck cancers. (11). Profound
tumor regression is common following treatment with OVs;
for example, durable objective responses were observed in 3/14
patients (hepatocarcinoma, lung cancer, and melanoma) follow-
ing treatment with vaccinia virus JX-594 in a phase I trial (7).
This virus has been deleted for viral thymidine kinase (TK),
making it dependent on cellular TK that is overexpressed in
cancer cells (7). In addition to the TK deletion that provides
tumor selectivity, the virus also expresses granulocyte macrophage
colony-stimulating factor (GM-CSF) to stimulate anti-tumor
immunity. Most recently, Amgen’s HSV-1-based talimogene laher-
parepvec (T-VEC) led to 16% durable response in a phase
III clinical trial for late-stage melanoma, and it is expected
that the company will file for FDA approval in North Amer-
ica in the coming year (12, 13). Like JX-594, T-VEC expresses
GM-CSF but has deletions in viral genes ICP34.5 and ICP47
that confer tumor selectivity and promote antigen presentation,
respectively (14).
While widespread approval and clinical implementation of
oncolytic virotherapy are in the foreseeable future, heterogene-
ity in clinical response to OVs remains a significant challenge as
evidenced from a number of early and late-stage human clinical
trials (6, 15, 16). This heterogeneity in response can be attributed to
factors that impact OV delivery and spread within tumors, such as
pre-existing immunity and remnant tumor anti-viral responses, as
well as to a variably immunosuppressive tumor microenvironment
that can prevent the generation of an effective anti-tumor immune
response. To overcome these challenges, it has been long recog-
nized in the OV field that improvements to therapeutic efficacy
either through viral engineering or through combination thera-
pies will be critical (6, 17). In the current review, we will focus
on advances in therapeutic strategies employing small-molecule
pharmacological agents that ameliorate OV treatment in vivo by
manipulating the innate and/or adaptive immune response to
virus and tumor (summarized in Table 1).
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Table 1 | Combinations of pharmacological and oncolytic therapies with demonstrated improvements in in vivo treatment efficacy.
Drug Mechanism of
action/molecular
target
Reported immunomodulatory
effect (systemic immunomodula-
tion or specific modulation of
anti-viral response
Oncolytic
virus
Reference
CLASSIC CHEMOTHERAPY AGENTS
Cyclophosphamide DNA alkylation Systemic immunomodulation HSV Ikeda et al. (20), Ikeda et al. (21),
Wakimoto et al. (22), and Currier et al. (24)
Adenovirus Thomas et al. (25), Dhar et al. (26), Cerullo
et al. (27), and Hasegawa et al. (28)
Vaccinia Lun et al. (29)
Reovirus Qiao et al. (30) and Kottke et al. (34)
Measles Ungerechts et al. (31) and Ungerechts
et al. (32)
Gemcitabine Nucleoside substitution
and inhibition of DNA
replication,
ribonucleotide
reductase inhibitor
Systemic immunomodulation Adenovirus Leitner et al. (38), Liu et al. (39), Onimaru
et al. (40), Bhattacharyya et al. (41),
Cherubini et al. (42), Wang et al. (43), and
Kangasniemi et al. (44)
Parvovirus Angelova et al. (45)
Reovirus Gujar et al. (48)
VSV Hastie et al. (49)
HSV Watanabe et al. (50) and Esaki et al. (51)
Vaccinia Yu et al. (52)
Myxoma Wennier et al. (53)
Bortezomib Proteasome inhibition Systemic immunomodulation VSV (VSV-mIFNβ) Yarde et al. (61)
Reovirus Carew et al. (62)
Adenovirus
(hTERT-Ad)
Boozari et al. (63)
Mitoxantrone Type II topoisomerase
inhibition
Systemic immunomodulation HSV Workenhe et al. (69)
Irinotecan Type I topoisomerase
inhibition
systemic immunomodulation HSV Tyminski et al. (74)
Sindbis Granot and Meruelo (75)
Temozolomide DNA alkylation Systemic immunomodulation Adenovirus Alonso et al. (80), Holzmuller et al. (81),
Liikanen et al. (82), and Tobias et al. (83)
HSV Aghi et al. (84) and Kanai et al. (85)
EPIGENETIC MODULATORS
Valproic acid Histone deacetylase
inhibition
Specific modulation of anti-viral
response
HSV Otsuki et al. (106)
Trichostatin A Histone deacetylase
inhibition
Specific modulation of anti-viral
response
HSV Liu et al. (105)
Vaccinia MacTavish et al. (108)
Entinostat (MS-275) Histone deacetylase
inhibition
Both VSV Nguyen et al. (99) and Bridle et al. (109)
5-Azacitidine DNA methyltransferase
inhibition
Specific modulation of anti-viral
response
HSV Okemoto et al. (111)
PI3K/Akt/mTOR PATHWAY INHIBITORS
LY294002 PI3K inhibition Specific modulation of anti-viral
response
HSV Kanai et al. (116)
(Continued)
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Table 1 | Continued
Drug Mechanism of
action/molecular
target
Reported immunomodulatory
effect (systemic immunomodula-
tion or specific modulation of
anti-viral response
Oncolytic
virus
Reference
Rapamycin mTORC1 and mTORC2
inhibition
Both Adenovirus Jiang et al. (120)
HSV Fu et al. (121)
VSV Alain et al. (122)
Everolimus
(RAD001)
mTORC1 inhibition Both Adenovirus Lukashev et al. (119)
OTHER
Viral sensitizer 1
(VSe1)
Unknown Specific modulation of anti-viral
response
VSV Diallo et al. (125)
Triptolide Global transcription
inhibition via RNA pol II
inhibition
Specific modulation of anti-viral
response
VSV Ben Yebdri et al. (130)
Sunitinib Receptor tyrosine
kinase inhibition
Specific modulation of anti-viral
response
VSV Kottke et al. (87) and Jha et al. (88)
Reovirus Kottke et al. (87)
Vaccinia Hou et al. (89)
Ipilimumab CTLA-4 inhibition Systemic immunomodulation NDV Zamarin et al. (138)
Numerous studies have shown that combining oncolytic virotherapy and pharmacological therapy leads to improved outcomes in vivo. This table summarizes these
reports, presenting the small molecule used in the study, its main mechanism of action or molecular target, its reported immuno-modulatory effect(s), and type of
oncolytic virus used. Abbreviations: HSV, herpes simplex virus; VSV, vesicular stomatitis virus; mIFNβ, murine interferon beta; hTERT-Ad, human telomerase reverse
transcriptase promoter-regulated adenovirus; PI3K, phosphoinositide 3-kinase; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin
complex 1; mTORC2, mammalian target of rapamycin complex 2; CTLA-4, cytotoxic T-lymphocyte antigen 4.
STANDARD CHEMOTHERAPEUTIC DRUGS THAT BOOST OV
ACTIVITY THROUGH SYSTEMIC EFFECTS ON IMMUNE CELLS
AND THE IMMUNE RESPONSE
Most cancer patients with advanced disease will be subjected to
some form of chemotherapy. This will largely depend on the
type of cancer and other salient pathophysiological characteris-
tics. Given that most patients enrolled in clinical trials to test
the efficacy of OVs suffer from advanced disease (7), a natural
trend in the OV field has been to test OVs in combination with
chemotherapeutics that are currently the standard of care. Classic
chemotherapy drugs typically capitalize on the fact that cancer cells
are continuously replicating unlike most normal cells (18). How-
ever, some normal cell types have higher replication rates, leading
to significant off-target effects. Hematopoietic cells among others
can be affected and this can lead to systemic immunosuppres-
sion (discussed below). While the evaluation of chemotherapeutic
drugs in the context of OV therapy has been fairly empirical
for the most part, their immunosuppressive effects can inher-
ently complement OV activity by increasing OV spread within
tumor beds and/or increasing anti-tumor immune responses. The
following sections provide an overview of classic chemotherapy
drugs that have been evaluated in combination with OVs focusing
on their anti-cancer mechanism of action, examples of OVs with
which they have been tested, and the mechanism by which these
agents suppress immunity and co-operate with OVs to improve
therapeutic outcomes.
CYCLOPHOSPHAMIDE
Cyclophosphamide (CPA) is a nitrogen mustard alkylating agent
that leads to cross-linking of nucleotides. Its active metabo-
lite, phosphoramide mustard, interferes with DNA replication
by forming guanine-to-guanine intra-strand and inter-strand
crosslinks (19). Aldehyde dehydrogenase (ALDH) catalyzes the
conversion of the immediate precursor of phosphoramide mus-
tard, aldophosphamide, to an inactive metabolite. Normal cells,
for example intestinal epithelial cells and bone marrow stem cells,
have a high level of ALDH, protecting them from the effects
of CPA’s toxic metabolites. In contrast, some lymphocytes have
a lower level of ALDH, which makes them more susceptible to
the effects of CPA. CPA has been used in combination with sev-
eral OVs including HSV-1 (20–24), adenovirus (25–28), vaccinia
(29), reovirus (30), measles (31–33), and vesicular stomatitis virus
(VSV) (33), leading to improved anti-tumor activity in vivo. Sev-
eral studies suggest that CPA can be efficacious in combination
with OVs by preventing immune-mediated viral neutralization
through inhibiting or delaying the rise of neutralizing antibod-
ies and depleting anti-viral immune cells including natural killer
(NK) cells, monocytes, macrophages, and lymphocytes (20, 22, 23,
25, 26). For example, one study showed that CPA inhibits tumor
infiltration of innate phagocytes (macrophages, microglia, and NK
cells) following HSV treatment in a syngeneic rat glioma model,
leading to increased viral persistence and improved overall efficacy
(23). Other studies suggest CPA can also enhance the generation of
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anti-tumor immunity by inhibiting regulatory T-cells (Tregs) (27,
34). Results from a first in-human clinical trial using Ad-GM-CSF
(CGTG-102) to treat solid tumors suggest that metronomic dos-
ing of CPA decreases Tregs without compromising the induction of
anti-tumor T-cell responses. This was found to be associated with
increased cytotoxic T-cell responses and the induction of Th1 type
immunity in most patients. The best progression-free survival and
overall patient survival rates were seen with the combination of
metronomic CPA and intratumoral infection of adenovirus (27).
GEMCITABINE
Gemcitabine is a fluorinated deoxycytidine nucleoside analog.
Incorporation of this analog into DNA prevents further addi-
tion of nucleosides during DNA polymerization and thereby halts
DNA replication and cell division. Gemcitabine also binds irre-
versibly to the active site of ribonucleotide reductase. As a result,
nucleotide production is halted and DNA replication ceases, lead-
ing to apoptosis in rapidly dividing cells [reviewed in Ref. (35)].
While gemcitabine can decrease neutralizing antibodies similar to
CPA (36), it is thought to promote anti-tumor immune responses
by off-target elimination of myeloid derived stem cells (MDSCs),
which suppress T-cell responses. Gemcitabine treatment thereby
increases the activity of CD4+ and CD8+ T-cells that recog-
nize tumor antigens (37). This drug has been shown to increase
the anti-tumor activity of a wide array of OVs including aden-
ovirus (38–44), parvovirus (45, 46), reovirus (47, 48), VSV (49),
HSV (50, 51), vaccinia (52), and myxoma virus (53). In the lat-
ter example, the anti-cancer activity of oncolytic myxoma virus
was improved using gemcitabine in disseminated pancreatic can-
cer murine models (53). Interestingly, no sensitization occurred
in immunocompromised mice, supporting the requirement for
a virus-triggered anti-tumor immune response in mediating the
combination effect. The combination of gemcitabine and reovirus
was recently evaluated in a phase I clinical trial and while anti-
tumor immune responses were not measured, neutralizing anti-
bodies against reovirus were decreased by gemcitabine treatment.
In this study, 80% of evaluable patients showed either partial
response or stable disease (36).
BORTEZOMIB
Bortezomib is a proteasome inhibitor approved to treat multiple
myeloma and mantle cell lymphoma. It reversibly binds the cat-
alytic site of the 26S proteasome with high affinity and specificity
(54). Bortezomib has been shown to inhibit NF-κB by preventing
degradation of IκB-α in some cell types (55) although the opposite
effect has also been observed (56). Other mechanisms of action by
which bortezomib may kill cancer cells are through ER-stress and
activation of the unfolded protein response (UPR) (57) and trig-
gering apoptosis by preventing the degradation of pro-apoptotic
proteins (56, 58). Some studies have shown that treatment of can-
cer cells using bortezomib increases surface expression of Hsp90
and Hsp60 in cancer cells leading to their more effective phago-
cytosis by dendritic cells (DCs), improving tumor vaccine effects
(59). Bortezomib-treated mice also exhibit increased DC matu-
ration and phagocytic potential (59). On the other hand, one
study found that bortezomib treatment leads to apoptosis of
allo-reactive CD4+ T-cells. Thus the net result on anti-cancer and
anti-viral immune responses is likely context-dependent (60).
Bortezomib has been tested in combination with oncolytic
VSV (61), reovirus (62), and adenovirus (63). Using VSV-mIFNβ,
combined treatment with bortezomib was inhibitory to virus
replication in myeloma cells in vitro but led to improved thera-
peutic efficacy compared to single treatments in syngeneic murine
myeloma models (61). Given no observed effect on tumor viral
load, this suggests bortezomib likely increases virus-induced cell
death and/or potentiates the anti-tumor response mediated by the
virus. Supporting the former, in combination with the oncolytic
adenovirus hTERT-Ad, bortezomib enhanced infection-induced
ER-stress and activated the UPR and UPR-associated apoptotic
cell death in vitro (63). In subcutaneous hepatocellular carci-
noma (HCC) mouse models, bortezomib refocused the immune
response toward tumor-associated antigens by inhibiting immune
recognition of the virus. This allowed for a reduction in viral dose
in the combination therapy while maintaining similar efficacy. It
was further demonstrated that bortezomib’s efficacy is dependent
upon a functional CD8+ T-cell response, as no response was seen
in vivo upon depletion of CD8+ T-cells.
MITOXANTRONE
Mitoxantrone is a type II topoisomerase inhibitor and a DNA
intercalating agent. Thus, it disrupts DNA synthesis and DNA
repair in both healthy cells and cancer cells (64). Mitoxantrone
was initially developed for treatment of cancer and has been
notably approved to treat leukemia and prostate cancer. How-
ever, due to its immunosuppressive effects, mitoxantrone was also
approved for the treatment of multiple sclerosis over a decade ago.
Similar to other immunosuppressive chemotherapies, its activ-
ity can be attributed to its effects on proliferating immune cells,
but it also has additional effects on antigen-presenting cells and
enhances suppressor T-cell functions. Mitoxantrone treatment
notably reduces the secretion of pro-inflammatory cytokines such
as IL-2, interferon-γ (IFN-γ), and tumor necrosis factor alpha
(65–68). This drug has been tested in combination with oncolytic
HSV-1 in syngeneic murine breast tumor models (69) but only
in vitro with adenovirus in prostate cancer cells (70–72). In the
case of the HSV-1 ICP0 null OV KM100, mitoxantrone was found
to induce immunogenic cell death and whereas no enhanced cell
killing was observed in vitro, the combination treatment improved
survival compared to single treatments in a Her2/neu TUBO-
derived syngeneic murine tumor model. This effect was associated
with increased intratumoral infiltration of neutrophils and tumor
antigen-specific CD8+ T-cells. It was also observed that CD8+
and CD4+ T-cells as well as Ly6G+ neutrophils were important
in mediating the improved anti-tumor efficacy.
IRINOTECAN
Irinotecan or more accurately its active metabolite SN-38 inhibits
topoisomerase I leading to a blockade in DNA replication and
transcription. It is mainly used in colon cancer as part of a reg-
imen known as FOLFIRI, which also includes folinic acid and
5-fluorouracil. This course of therapy has been found to reduce the
number of Tregs in colorectal cancer patients with minimal impact
on total lymphocyte and CD4+ T-cells counts (73). Few studies
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have used irinotecan in combination with OVs in vivo. One study
showed that HSV-1 expressing CYP2B1, which converts irinote-
can into SN-38, leads to improved survival in combination with
irinotecan as compared to virus or drug alone in an immunode-
ficient mouse glioma model (74). While potential immunological
effects were not assessed, a likely contributor to the effect of com-
bination therapy is the increased conversion of irinotecan to active
SN-38 due to the expression of CYP2B1 by the virus. Another study
used oncolytic Sindbis to treat immunodeficient mice bearing
human ovarian tumors (75). In this model irinotecan improved
the oncolytic efficacy of Sindbis and this effect required NK cells.
TEMOZOLOMIDE
Temozolomide (TMZ) is an alkylating agent that leads to alkyla-
tion/methylation of DNA and has demonstrated clinical benefits
in patients with glioblastoma (GBM) (76) and advanced metasta-
tic melanoma (77). At higher doses, TMZ can be myeloablative
and in these conditions, CD4+ and CD8+ T-cells, as well as
Tregs are markedly reduced. Vaccination using an anti-tumor
peptide vaccine following TMZ-induced myeloablation leads to
improved CD8+ T-cell anti-tumor responses and prolongs sur-
vival in a murine model of established intracerebral tumors (78).
However, Treg depletion has also been observed following low-
dose TMZ in rats (79). Oncolytic adenovirus (80–83) and HSV
(84, 85) have been tested in vivo in combination with TMZ,
albeit immune effects have not been systematically explored. In
one study with Ad5/3-D24-GM-CSF± low-dose CPA (to reduce
Tregs), treatment with TMZ increased tumor cell autophagy,
anti-tumor immunity, and ultimately reduced tumor burden in
murine models of xenogeneic prostate cancer (82). When used in
chemotherapy-refractory patients, adenovirus infusion followed
by TMZ treatment was found to increase tumor-specific T-cells
and immunogenic cell death as well as overall survival compared
to adenovirus treatment alone.
SUNITINIB
Sunitinib is an oral, small-molecule, and multi-targeted receptor
tyrosine kinase (RTK) inhibitor that was approved by the FDA for
the treatment of metastatic renal cell carcinoma (RCC) and gas-
trointestinal stromal tumors (GIST) in 2006. Since then it has also
been approved for use in neuroendocrine pancreatic cancer. Suni-
tinib inhibits cellular signaling by targeting multiple RTKs. These
include platelet-derived growth factor receptors (PDGF-R) and
vascular endothelial growth factor receptors (VEGF-R). Sunitinib
also inhibits KIT (CD117), the RTK that drives the majority of
GISTs. In addition, sunitinib inhibits other RTKs including RET,
CSF-1R, and FLT3. Sunitinib has been recently shown to have
additional off-target effects that block effector proteins of the IFN
signaling pathway such as RNaseL and PKR (86).
Sunitinib has been evaluated in combination with VSV (87,
88), reovirus (87), and vaccinia virus (89). In the context of VSV
oncovirotherapy, sunitinib decreased phosphorylation of the PKR
substrate eIF2-α, leading to increased viral titers in vitro. Quite
remarkably, combination therapy resulted in complete and sus-
tained tumor regression in several immunodeficient and immuno-
competent mouse tumor models (88). However, sunitinib may
have additional effects on the infectivity of tumor vasculature.
One study used sunitinib to transiently inhibit VEGF signaling,
creating a “VEGF burst” upon treatment recovery. In combina-
tion with oncolytic VSV and reovirus, this led to increased viral
infection and endothelial cell lysis as well as virus spread from
blood vessels to cancerous tissues (87). A recent study looked at
the combined effect of sunitinib and oncolytic vaccinia virus in
syngeneic kidney and breast cancer mouse models, and found the
combined treatment led to the most dramatic tumor reduction.
Infection of tumors with oncolytic vaccinia as a monotherapy led
to decreased VEGF expression (89), in line with the observation
that vaccinia induces tumor vascular shutdown in both murine
tumor models and in patients (90–92). Thereby, the combination
effect in this study was attributed to enhanced tumor devascular-
ization, although other potential effects of sunitinib on the cellular
anti-viral response cannot be ruled out.
DRUGS THAT EPIGENETICALLY REPROGRAM IMMUNE
RESPONSES TO ENHANCE OV THERAPY
Epigenetic changes in gene regulation and expression can lead to
phenotypic heterogeneity in genetically identical cell populations.
Through reversible modifications to DNA and chromatin struc-
tures by enzymes targeting DNA, histones, and the distribution
pattern of nucleosomes, the ability of transcriptional factors to
access their respective promoters can be deeply altered (93). Not
surprisingly, many enzymes that are involved in epigenetic regu-
lation are deregulated in cancer and manipulation of the cancer
epigenome using small molecules has been explored successfully
as a treatment modality for cancer. As will be discussed in the
following sub-sections, modification of the cancer epigenome has
also proven beneficial to improve oncolytic virotherapy through
effects on the cellular anti-viral response, the anti-tumor immune
response, and even viral gene expression [for a more extensive
review, refer to Ref. (1)].
HDAC INHIBITORS
Transformed cells often have defective IFN signaling pathways
due to the cytokine’s ability to suppress cellular proliferation
and stimulate immune responses, both of which cancer cells
must bypass in order to evolve to full-blown malignancies (94–
96). Indeed, it has been estimated that roughly three quarters
of tumor cell lines within the NCI60 panel have defective IFN
responses (97). Numerous reports have attributed dysfunctional
IFN pathways in tumors to epigenetic silencing including DNA
promoter hypermethylation and transcriptionally suppressive his-
tone modifications [reviewed in Ref. (1)]. The extent to which
interferon-stimulated genes (ISGs), the effector arsenal of the IFN-
mediated anti-viral response, are epigenetically silenced can lead
to differences in the sensitivity to virus infection (98–102). Impor-
tantly, transcriptional activation of ISGs has been shown to require
histone deacetylase (HDAC) activity (103), which has spawned
the evaluation of HDAC inhibitors (HDIs) in combination with
several OVs.
HDAC inhibitors including valproic acid (VPA), trichostatin
A (TSA), suberoylanilide hydroxamic acid (SAHA), and MS-275
have all been used in the context of OV therapy to effectively
“reprogram” IFN-responsive tumors to become permissive to OV
infection. HDIs such as VPA and TSA were found to enhance
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HSV oncolysis in oral squamous carcinoma cells (SCC) (104) and
glioma tumors (105–107). In one report, this was attributed to an
inhibition of virally induced ISG expression, even in the presence
of exogenously added IFNβ (106). The result of HDI/HSV combi-
nation therapy led to prolonged survival in several murine tumor
models (105, 106). TSA also enhanced the oncolytic capacity of
vaccinia virus, where the two agents synergistically increased cell
killing in vitro in several cancer cell lines and the combination ther-
apy led to improved survival responses in syngeneic lung metasta-
sis and subcutaneous colorectal carcinoma mouse models (108).
Similarly, MS-275 (entinostat), SAHA (vorinostat), and other
HDIs robustly sensitized resistant cells to VSV-mediated oncol-
ysis by suppressing transcription of IFNβ and ISGs, increasing
viral titers, and increasing cancer cell death. This potent synergy
was cancer cell-specific and led to delayed tumor progression in
xenograft models and improved viral spread within tumors in a
syngeneic metastatic breast cancer model (99). While only evalu-
ated in vitro in this study, HDI treatment of several cancer cell lines
increased spreading of vaccinia and Semliki Forest viruses as well.
This activity was ultimately linked to HDI-elicited dampening of
the response to IFN (99).
In addition to the effects of HDIs on the response to IFN, evi-
dence suggests HDIs can have additional immuno-modulatory
properties. Particularly striking effects of HDIs have been observed
in the context of a heterologous oncolytic prime-boost strat-
egy, where mice with syngeneic B16 melanoma brain tumors
were first primed with an oncolytic adenovirus expressing the
tumor-associated antigen dopachrome tautomerase (hDCT, over-
expressed in B16) then treated with oncolytic VSV expressing
hDCT. MS-275 given along with VSV-hDCT potentiated the anti-
tumor response to hDCT while suppressing the adaptive anti-viral
response, ultimately redirecting the immune response toward the
tumor. As a result, efficacy was dramatically improved, where the
majority of mice given MS-275 in the prime-boost regime experi-
enced long-lasting (>200 day) cures, compared to 100% mortality
before day 50 in the mice given the same therapy minus MS-275
(109). In this study, it was also shown that MS-275 reduced virus
neutralizing antibodies and memory CD8+ T-cells while main-
taining prime-induced levels of humoral and cellular immunity
against the tumor antigen (109).
5-AZA
DNA methylation and histone modifications are highly inter-
dependent epigenetic processes (110). In addition to histone
acetylation-mediated gene silencing, ISGs and other genes implicit
in the IFN-mediated anti-viral response are often silenced in
cancers by DNA hypermethylation at CpG islands in their pro-
moter region [reviewed in Ref. (1)]. In addition to cellular genes,
viral genomes can also be susceptible to direct epigenetic silenc-
ing. For example, oncolytic HSV rQNestin34.5 is transcriptionally
silenced upon infection of glioma cells, due to increased DNA
methylation levels at the virally encoded mammalian Nestin pro-
moter (111). As such, some groups have investigated using OVs
in combination with 5-AZA-2′-deoxycytidine (5-AZA): a DNA
methyltransferase inhibitor that prevents DNA methylation and
allows silenced DNA to regain accessibility to transcription fac-
tors. In the case of oncolytic HSV rQNestin34.5, treatment with
5-AZA was sufficient to de-repress transcription under control of
the Nestin promoter, allowing viral gene expression, increased viral
replication, and HSV-mediated glioma cell killing. This translated
to increased survival in glioma bearing mice treated with both
5-AZA and the OV, compared to either treatment administered
alone (111). However, it is interesting to mention that in the same
study, VPA an HDAC inhibitor was sufficient to drive down DNA
methylation at the Nestin promoter in vitro in infected glioma cells,
highlighting the closely interrelated impact of DNA methylation
and histone modification (111).
PI3K/Akt/mTOR PATHWAY INHIBITORS
The phosphoinositide 3-kinase (PI3K) pathway is critical to cell
survival/apoptosis signaling in response to stress. Genetic muta-
tions in the P13K pathway frequently occur in cancers resulting
in dysfunctional apoptotic responses and pro-survival signaling
(112). Various growth hormones and stress signals including IFN-
α activate PI3K, which triggers a signaling cascade leading to Akt
phosphorylation (112, 113). This activates the kinase, which then
phosphorylates a number of cellular factors involved in cell sur-
vival and proliferation such as NF-κB, which is also involved in
inducing the type I IFN cascade.
Several PI3K pathway inhibitors including GDC-0941 and
NVP-BEZ235 are currently being clinically evaluated for the treat-
ment of cancer (114). Both GDC-0941 and LY294002, a common
PI3K inhibitor chemical probe, inhibit PI3K activity via competi-
tive inhibition of an ATP binding site on the p85α subunit (115).
The PI3K inhibitors LY294002, GDC-0941, BEZ235, as well as the
Akt inhibitor tricibine, acted synergistically with oncolytic HSV
MG18L to induce apoptosis in glioma cell lines in vitro in a cancer
cell-specific manner. Remarkably, combination therapy resulted
in durable cures in mice bearing glioblastoma multiforme (GBM)
tumors, surpassing the efficacy of either therapy administered
alone (116). Recent findings also indicated LY294002 increased
killing of multiple myeloma cells in vitro triggered by the oncolytic
adenovirus ZD55-TRAIL (117).
Mammalian target of rapamycin (mTOR), a master regulator
of cellular translation, is downstream of PI3K and Akt signal-
ing. Indeed, both GDC-0941 and NVP-BEZ235, a PI3K inhibitor
developed by Novartis, have been reported to inhibit mTOR as
well as PI3K (114). While mTOR controls translation of a host of
cellular mRNAs and can also impact translation of viral proteins,
evidence suggests it can control the anti-viral response by regulat-
ing translation of IFN and other key mediators of the anti-viral
response such as IRF-7 (118). The mTOR inhibitor rapamycin,
a well-known immunosuppressant, has been tested in combina-
tion with several OVs including oncolytic adenovirus (119, 120),
HSV (121), VSV (122), and myxoma (123, 124). Treatment with
rapamycin or closely related mTOR inhibitors such as everolimus
(RAD001) has been reported to suppress the adaptive immune
response to OVs by reducing levels of antibodies generated against
the viruses (120), improving OV activity in several rodent models
of cancer (119–121). In one study, enhancement of OV activity was
also observed in vitro following treatment with rapamycin (121).
This may be due to the impact of rapamycin on the IFN response
as determined from another study where rapamycin was shown to
reduce levels of VSV-induced IFN in rats, improving VSV efficacy
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in an aggressive rat glioma model (122). Interestingly, oncolytic
myxoma is enhanced by rapamycin in normally resistant human
tumor cells in vitro; however, the mechanism by which this occurs
is thought to be due to rapamycin-induced increases in Akt kinase
levels optimal for sustaining myxoma replication (123).
OTHER PROMISING IMMUNO-MODULATORY
OV-ENHANCING DRUGS
NOVEL VIRAL SENSITIZERS
The paragraphs above have shown countless examples of empir-
ically or rationally selected combination therapeutic approaches
aiming to improve the activity of OVs using well-characterized
chemotherapeutics and signaling pathway inhibitors. A high-
throughput screen was performed in an effort to expand this
approach in an unbiased manner to identify previously unchar-
acterized small molecules that enhance OV activity. This screen
was performed using oncolytic VSV∆M51 in the resistant murine
breast cancer cell line 4T1 (125). Several molecules were identified
as novel “viral sensitizers” (VSes) that were capable of boosting
VSV replication and spread in vitro. One of these compounds,
VSe1, boosted VSV∆M51 replication by up to 1000-fold, and was
found to synergistically increase tumor cell killing. The mode
of action of VSe1 is not fully understood but at a minimum it
involves disruption of the IFN response. More specifically, ISGs
typically triggered upon VSV infection remained silenced in cells
pre-treated with VSe1 (125). When used as a combination therapy
to treat an aggressive mouse colon carcinoma model refractory to
VSV∆M51,VSe1 potentiated OV activity leading to delayed tumor
progression in the context of the combination treatment, while
either VSV∆M51 or VSe1 alone had no appreciable anti-cancer
effects (125).
TRIPTOLIDE
Triptolide (TPL) is a naturally derived component of the Chinese
herb Tripterygium wilfordii and has been used for centuries as
an anti-inflammatory remedy that has also been found to have
anti-cancer properties (126–128). TPL is known to be a global
transcription inhibitor and has multiple effects including the inhi-
bition of RNA polymerase II and the expression of genes involved
in apoptosis and NFκB signaling (129). A recent report found
that TPL also suppresses IFN signaling downstream of IRF3 (130).
When combined with oncolytic VSV both in vitro in VSV-resistant
tumor cells and in vivo in an aggressive mouse GBM tumor
model, the two therapies synergistically improved tumor-specific
virus replication leading prolonged survival and delayed tumor
progression compared to either therapy given alone (130).
JAK KINASE INHIBITORS
Ruxolitinib (Jakafi) is a Jak1/2 kinase inhibitor (131) approved in
2011 for the treatment of myelofibrosis (132). Patients with myelo-
proliferative neoplasms often possess an activating mutation in
the gene encoding Jak2 (133), resulting in aberrant inflammatory
cytokine release and splenomegaly. Treatment with ruxolitinib,
while not targeting the genetic determinant of the neoplasm, led
to profound resolution of severe symptoms in human trials to
treat myelofibrosis (splenomegaly, weight loss, fatigue), and this
clinical efficacy was associated with a potent reduction in inflam-
matory cytokine levels (134). Given that Jak1 is required for type
I IFN signaling and induction of ISGs, Jak1 inhibitors have the
potential to benefit OV therapy in IFN-responsive tumors. Both
ruxolitinib and Jak inhibitor 1 were sufficient to sensitize VSV-
resistant squamous cell carcinoma cells in vitro to VSV infection,
and this sensitization was associated with marked decreases in
ISG expression (135). Pre-treatment with the Jak inhibitor 1 also
sensitized sarcoma and bladder carcinoma cells to VSV infection
in vitro (136).
CHECKPOINT INHIBITORS
Targeting T-cell inhibitory check point molecules, including the T-
cell inhibitory receptor cytotoxic T-lymphocyte antigen 4 (CTLA-
4) and programed cell death 1 (PD1), is a relatively new therapeutic
approach to cancer therapy. During normal immune responses,
T-cell checkpoint receptors such as PD1 and CTLA-4 prevent over-
active T-cell responses, which can lead to harmful tissue damage.
However in cancers, tumor infiltrating T-cells are often inhibited
by both PD1 and CTLA-4 stimulation. As a result, T-cell anergy is a
major barrier to immune-mediated tumor recognition and clear-
ance. Given the ability of OVs to stimulate an anti-tumor immune
response, combining OV with checkpoint inhibitors has emerged
as a logical combination approach. While several groups are cur-
rently working on this approach, published studies to date have
focused on ipilimumab, an anti-CTLA-4 antibody approved to
treat melanoma in 2011. By targeting CTLA-4, ipilimumab blocks
interaction with its ligands, CD80/CD86, leading to increases in T-
cell mediated anti-tumor responses. Anti-CTLA-4 antibodies have
been used in combination with oncolytic parvovirus in vitro (137)
and Newcastle disease virus (NDV) in vivo to treat murine B16
melanoma (138). Remarkably, the combination therapy of NDV
and anti-CTLA-4 led to nearly 70% cures in a B16 melanoma
mouse model compared to 20% cures for anti-CTLA-4 antibody
alone and no effect of the OV on its own (138). Notably, NDV com-
plemented with anti-CTLA-4 led to an increase in the infiltration
of activated CD8+ and CD4+ T-cells and a reduction in Tregs.
CONCLUSION
Successful therapy using OVs will ultimately depend on effectively
navigating the delicate balance between the anti-viral response
and the anti-tumor immune response such as to minimize the for-
mer in the short term and maximize the latter in the long term.
As outlined above, several approved drugs and novel small mol-
ecules can be effective tools to dampen the innate and adaptive
anti-viral responses, increase the anti-tumor immune response, or
both. However, given the close interplay between the cellular anti-
viral response and the adaptive immune response that is required
for prolonged tumor control, OV/drug scheduling is likely to be
critical. To this end, it is probable that the combination of some of
the agents described above may allow for additional flexibility and
more effective therapy. For example, one can easily foresee first
using a drug that specifically dampens the cellular antiviral to per-
mit robust OV replication followed with another that promotes
the generation of an anti-tumor response. However, given the effi-
cacy of each approach is undoubtedly both context-dependent
(e.g., tumor type and tumor site) and OV-dependent, more pre-
clinical and clinical studies will be necessary to identify winning
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combinations that can maximize the potential for curing cancers
in a clinical context.
While many studies demonstrate therapeutic benefit of com-
bination therapies at least in animal models, we can perceive
a deficit in regards to systematic head-to-head comparisons of
different combination therapies coupling OVs and the immune-
modulatory drugs reviewed above. While such a feat may prove
daunting experimentally, this exercise seems warranted and neces-
sary to delineate a more educated choice of combination therapies
to push forward into clinical trials. One clear trend overall is
that evaluation of promising combination therapies with novel
immuno-modulatory agents seems to stop at the pre-clinical level.
There are likely several factors that contribute to this. For exam-
ple, companies developing novel small molecules may be reluctant
to explore combinations with OVs that are still relatively novel
themselves. Similarly, novel small molecules need to be validated
clinically, which complicates clinical trial design and adds addi-
tional risk from the perspective of those spearheading clinical
translation of OVs. This is particularly challenging for novel small
molecules such as VSe1, which have been selected for the sole
purpose of enhancing OV activity (125). This type of small-
molecule/OV co-development can only be reasonably achieved
by pharmaceutical companies that have experience in developing
both small-molecule and biological therapies separately. Hence,
from a clinical perspective, it is likely that the combination of OV
therapy with a chemotherapy drug that is part of current standard
of care would be the easiest to implement as demonstrated with the
combination of oncolytic adenovirus and CPA (27). With promis-
ing results emerging from the clinic showing benefits combining
OVs with traditional chemotherapy drugs, and as pharmaceuti-
cal companies such as Amgen begin to take heed of the potential
of OV therapy for the treatment of cancer, clinical evaluation of
some of the more novel OV-synergizing compounds seems likely
in the near future as a means to overcome heterogeneity in clinical
response.
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